Company intelligence / Profile preview

Senzer

Salisbury, Wiltshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Senzer developed and CE-marked a Class IIa pharmaceutical inhaler for dose-controlled systemic delivery of cannabinoids and repurposed small-molecule drugs, generating real‑world evidence through participation in Europe's first national medical cannabis registry (Project TWENTY21). The company also pursued reformulated inhaled antivirals for COVID‑19 via a critical care division, but no late‑stage or registrational clinical data are publicly reported.[2][6]

Therapeutic areas: PsychiatryPulmonologyNeurologyInfectious Diseases
Modalities: DeviceSmall molecule
Industry: Therapeutic Medical Devices

Partnerships

Insys Therapeutics (in-licensing of cannabinoid inhalation technology)[1]Drug Science / Project TWENTY21 (UK medical cannabis registry)[2][5]

Beyond the preview

Go deeper on Senzer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senzer.

Explore the full profile